Visas open door for US FDA to ramp up drug inspections in China
This article was originally published in SRA
Executive Summary
China's decision finally to grant visas that will result in an increase in the number of US Food and Drug Administration drug inspectors stationed in the country appears to mark a willingness by the authorities to open up China’s pharmaceutical manufacturing activities to wider outside scrutiny1.